Kymera Therapeutics Announces Major Stock Offering

Kymera Therapeutics ( (KYMR) ) just unveiled an update.

On December 9, 2025, Kymera Therapeutics announced an underwritten public offering of 7,000,000 shares of its common stock at $86.00 per share, expected to close on December 11, 2025. The company anticipates net proceeds of approximately $656.1 million, which will be used to advance its degrader programs and for general corporate purposes. The offering, managed by major financial institutions, includes an option for underwriters to purchase an additional 1,050,000 shares. This move is expected to support Kymera’s operations into 2029, enhancing its market position and stakeholder value.

The most recent analyst rating on (KYMR) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Spark’s Take on KYMR Stock

According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.

Kymera Therapeutics’ overall stock score is driven by significant financial challenges, despite strong technical momentum and positive corporate developments. The company’s financial instability and negative cash flows weigh heavily on the score, but recent clinical advancements and strategic partnerships provide a positive outlook.

To see Spark’s full report on KYMR stock, click here.

More about Kymera Therapeutics

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted protein degradation (TPD) therapies. The company aims to address critical health issues by creating oral small molecule degraders for immunological diseases, offering a new generation of effective treatments.

Average Trading Volume: 892,322

Technical Sentiment Signal: Buy

Current Market Cap: $6.78B

Find detailed analytics on KYMR stock on TipRanks’ Stock Analysis page.